Peritoneal Carcinomatosis from Colorectal Cancer

Sommariva, Antonio; Rossi, Carlo Riccardo

doi:10.1007/978-88-470-5711-1_19

Cited by 1 publication

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the small intestine serosa is spared in the early stages of PC due to the peristaltic motility preventing tumor cell adhesion. Collectively, peristaltic movement of the bowel, fluid absorption, gravity, and tumor characteristics determine the pattern of tumor spread in the peritoneum known as neoplastic redistribution [18, 19]. …”

Section: Pathophysiology Of Peritoneal Carcinomatosis From Gi Malignamentioning

confidence: 99%

“…With smaller residual disease, chemotherapy should be more effective in treating the disease, thus reducing the time for the cells to divide and to develop drug-resistant clones [18]. …”

Section: Rationale For Cytoreduction and Hipecmentioning

confidence: 99%

“…The aim of CRS is to remove all visible disease with a target of complete cytoreduction (no visible tumor) to allow HIPEC to have an optimal effect [18]. The oncological principles of peritonectomy and CRS were first described by Sugarbaker.…”

Section: Surgical Techniquementioning

confidence: 99%

“…Moreover, they should have no severe direct local toxicity, have low systemic toxicity, have known efficacy against the tumor type treated, and have a synergistic effect with heat [18]. Different regiments of single or combination chemotherapies have been used in HIPEC procedures including mitomycin-C +/− doxorubicin or +/− cysplatin, oxaliplatin, and cisplatin + doxorubicin [38].…”

Section: Chemotherapy Agentsmentioning

confidence: 99%

See 3 more Smart Citations

Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: the Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion

Nassour

Polanco

2017

Curr Colorectal Cancer Rep

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is a disease with a poor prognosis, often thought to be a terminal illness with no hope except for palliative treatment. New therapeutic modalities combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown favorable outcomes and may provide a significant survival benefit in a selected group of patients. The main rational for CRS is to remove all visible tumor burden to allow for the chemotherapeutic agent (HIPEC) to eradicate any microscopic residual disease. The Amsterdam statement formulated at the 9th International Congress on Peritoneal Surface Malignancies supports the use of CRS with HIPEC as a standard of care for selected patients with small-to-moderate volume PC from CRC. Selecting appropriate patients who would benefit from CRS/ HIPEC is paramount to derive the maximum oncological outcomes while minimizing the risks of postoperative complications and mortality. In this paper, we will review the role for CRS/HIPEC in the management of PC from CRC.

show abstract

Section: Pathophysiology Of Peritoneal Carcinomatosis From Gi Malignamentioning

confidence: 99%

“…With smaller residual disease, chemotherapy should be more effective in treating the disease, thus reducing the time for the cells to divide and to develop drug-resistant clones [18]. …”

Section: Rationale For Cytoreduction and Hipecmentioning

confidence: 99%

Section: Surgical Techniquementioning

confidence: 99%

Section: Chemotherapy Agentsmentioning

confidence: 99%

See 2 more Smart Citations